Cover Image
市場調查報告書

Akron Molecules AG 產品平台分析

Akron Molecules AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 307308
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Akron Molecules AG 產品平台分析 Akron Molecules AG - Product Pipeline Review - 2015
出版日期: 2015年02月28日 內容資訊: 英文 27 Pages
簡介

Akron Molecules AG 是總公司在奧地利的生物科技企業,有幾個臨床階段的開發中產品。擁有針對疼痛、肥胖的領域的產品系列。

本報告提供Akron Molecules AG 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Akron Molecules AG 基本資料

  • Akron Molecules AG 概要
  • 主要資訊
  • 企業資料

Akron Molecules AG :R&D概要

  • 主要的治療範圍

Akron Molecules AG :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Akron Molecules AG :開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Akron Molecules AG :藥物簡介

  • AKR-202
  • AKR-101
  • AKR-210
  • AKR-303
  • AKR-102
  • AKR-201
  • Drug for Lymphoma

Akron Molecules AG :開發平台分析

  • 各給藥途徑
  • 各分子類型

Akron Molecules AG :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06816CDB

Summary

Global Markets Direct's, 'Akron Molecules AG - Product Pipeline Review - 2015', provides an overview of the Akron Molecules AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Akron Molecules AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Akron Molecules AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Akron Molecules AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Akron Molecules AG's pipeline products

Reasons to buy

  • Evaluate Akron Molecules AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Akron Molecules AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Akron Molecules AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Akron Molecules AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Akron Molecules AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Akron Molecules AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Akron Molecules AG Snapshot
    • Akron Molecules AG Overview
    • Key Information
    • Key Facts
  • Akron Molecules AG - Research and Development Overview
    • Key Therapeutic Areas
  • Akron Molecules AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Akron Molecules AG - Pipeline Products Glance
    • Akron Molecules AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Akron Molecules AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Akron Molecules AG - Drug Profiles
    • AKR-202
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AKR-203
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AKR-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AKR-210
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AKR-303
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AKR-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AKR-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Lymphoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Akron Molecules AG - Pipeline Analysis
    • Akron Molecules AG - Pipeline Products by Route of Administration
    • Akron Molecules AG - Pipeline Products by Molecule Type
  • Akron Molecules AG - Dormant Projects
  • Akron Molecules AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Akron Molecules AG, Key Information
  • Akron Molecules AG, Key Facts
  • Akron Molecules AG - Pipeline by Indication, 2015
  • Akron Molecules AG - Pipeline by Stage of Development, 2015
  • Akron Molecules AG - Monotherapy Products in Pipeline, 2015
  • Akron Molecules AG - Phase II, 2015
  • Akron Molecules AG - Phase I, 2015
  • Akron Molecules AG - Preclinical, 2015
  • Akron Molecules AG - Discovery, 2015
  • Akron Molecules AG - Pipeline by Route of Administration, 2015
  • Akron Molecules AG - Pipeline by Molecule Type, 2015
  • Akron Molecules AG - Dormant Developmental Projects,2015

List of Figures

  • Akron Molecules AG - Pipeline by Top 10 Indication, 2015
  • Akron Molecules AG - Pipeline by Stage of Development, 2015
  • Akron Molecules AG - Monotherapy Products in Pipeline, 2015
  • Akron Molecules AG - Pipeline by Top 10 Route of Administration, 2015
  • Akron Molecules AG - Pipeline by Top 10 Molecule Type, 2015
Back to Top